USP9X and myeloproliferative disorder: Thus, the present study proposes USP9X inhibitors along with BH3 mimetics as promising agents for novel therapeutic strategies against JAK2-V617F-positive myeloproliferative neoplasms, particularly under the ruxolitinib persistence condition.